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Abstract 
Bone morphogenetic proteins (BMPs) are deposited in bone and responsible for 
osteoinduction. At present there is essentially one product on the market mainly used for 
spinal fusion purposes where a bovine collagen fleece is applied as delivery system. Now, 
with the expiration of the patent protection new products utilizing other delivery systems will 
soon hit the market. The interplay between delivery system and BMP, resulting in a 
characteristic release profile, is crucial for clinical success. We here report on two apatite 
based commercially available granules which could potentially be used in a combination 
product with recombinant human BMP-2 (rhBMP-2). Regardless of their similar chemistry, 
their interaction with rhBMP-2 differs. Deproteinized bovine bone matrix (DBBM), a clinically 
well-established bone substitute, has a high affinity to rhBMP-2 and releases only 50% of the 
growth factor during the first two weeks in vitro. Activity of the physio-adsorbed rhBMP-2 is 
indicated by an enhanced bone augmentation in vivo. In contrast, all rhBMP-2 delivered in 
combination with synthetic hydroxyapatite/β-tricalcium phosphate (HA/TCP) granules is 
released during the first 24 h. Bone to implant contact is significantly increased for HA/TCP in 
combination with rhBMP-2 but is still below the level of DBBM alone. For both HA/TCP and 
DBBM, the released rhBMP-2 is active in vitro. Our results suggest that the different release 
behavior from these two apatite granules is due to the 1000 fold higher specific surface area 
of DBBM compared to HA/TCP. The sustained release from DBBM suggests that it could be 
used as a safe delivery system, possibly allowing a reduction of clinical doses of rhBMP-2.
1. Introduction 
Bone morphogenetic proteins (BMPs) are growth factors associated with osteoinduction [1]. 
They recruit and stimulate adult mesenchymal stem cells and preosteoblastic cells to 
migrate, proliferate and mature into osteoblasts [2, 3]. Currently, recombinant human BMP-2 
(rhBMP-2) in combination with a collagen carrier (Infuse®, Medtronic Sofamor Danek, 
Memphis, Tennessee) is clinically used for lumbar spine fusion and persisting long bone 
defects. Despite the fact that the application of rhBMP in the clinic is associated with 
moderate to severe side effects, in particular when used off label as reviewed in [4], the 
expiration of the patent protection for BMPs will soon yield in new products containing BMPs. 
One of the side effects, the development of cancer, is linked to a very high rhBMP-2 dosage. 
The data presented to the US Food and Drug Administration (FDA) on the planned product 
AMPLIFY™ (Medtronic Sofamor Danek, Memphis, Tennessee) revealed a higher number of 
cancers in the investigational group compared with the control and led to the disapproval of 
this product [5]. In essence, this product contained 40 mg of rhBMP-2 on a 20 cc 
compression-resistant matrix consisting of 15% hydroxyapatite and 85% β-tricalcium 
phosphate. Lower dosages of 1.5 mg rhBMP-2 per ml graft volume as found in Infuse® 
(Medtronic Sofamor Danek, Memphis, Tennessee) have not been associated with a higher 
incidence rate for cancer [5]. Here the major side effect is swelling [6]. Therefore more 
efficient BMP delivery systems have to be developed where lower amounts of BMP show 
efficiency.  
Bone regeneration is based on osteoconduction, which is the ingrowth of bone into 3-
dimensional structures and osteoinduction, which is based on the recruitment and stimulation 
of mesenchymal stem cells and osteoprogenitor cells to form bone. The transplantation of 
bone cells is of advantage for the regeneration, if a bone substitute material is applied to 
facilitate the regeneration [7].  An autologous bone graft contains bone cells per se. Any 
other source, however, and in vitro tissue engineering approaches in particular will certainly 
increase the costs and efforts substantially and might only be legitimate to be applied in a 
very limited number of cases. For many clinical cases with small bone defects an 
osteoconductive bone substitute is sufficient. For larger or even critical sized defects, 
osteoinductive bone substitute materials may render the application of bone cells redundant. 
Osteoinductive bone materials can be developed by an optimization of the chemical 
composition, surface topography, and geometry of the biomaterial, which in turn affect 
resorption rate and cell-material interactions [8] or by the combination of a bone substitute 
material with BMPs. Due to the similar chemical composition of natural bone, calcium-
phosphate based materials are promising candidates for the development of osteoinductive 
bone substitutes of either type. Human bone mineral has been shown to be a promising 
candidate [9]. Deproteinized bovine bone matrix (DBBM), being the gold standard bone 
substitute material in dentistry and having a very similar chemistry and structure compared to 
human bone, would be a clinically well-accepted choice. 
Synthetic materials performing equally, however, would be advantageous, since the 
adjustment range of parameters would be simpler, the production would be possible on 
larger scales, and there would be no conflicts with religious beliefs of patients regarding 
implantation of a material derived from another living organism. Many synthetic calcium 
phosphate based materials are therefore under investigation as bone substitute materials 
[10, 11] as such or as osteoinductive ceramics [8, 12]. 
The combination of ceramics with BMPs to render them osteoinductive is a strategy used by 
nature. It has been shown that rhBMP-2 has a higher affinity to hydroxyapatite compared to 
other proteins [13]. The mechanisms of protein adsorption to hydroxyapatite are a very 
complex interplay of various parameters [14-16]. Surface roughness plays a distinct role in 
protein adsorption to surfaces in general, including hydroxyapatite [17-19]. The specific 
surface area is certainly another important aspect [20]. For rhBMP-2 in particular, the 
presence of calcium ions and a slightly acidic pH increase the adsorption of rhBMP-2 from 
solutions [13, 19]. 
In a recent study we have investigated the differences in interactions of glycosylated and 
non-glycosylated rhBMP-2 with DBBM and hydrolysable mPEG hydrogels [21].  Observed 
strong affinities of both rhBMP-2 variants to DBBM, indicated that DBBM alone might be 
sufficient as a carrier. This would result in a simpler system and make any decrease of 
rhBMP-2 activity due to an additional delivery system irrelevant. 
We here evaluate clinically applied hydroxyapatite based bone substitute materials as 
carriers for non-glycosylated rhBMP-2. By radioactive iodine (125I) labeling both rhBMP 2 in 
solution and adsorbed to hydroxyapatite granules could be detected in parallel in trace 
amounts using a gamma counter. This allowed the determination of rhBMP-2 release profiles 
and bioactivity in vitro.  The relevance of these findings on material growth factor interactions 
for the in vivo situation was then tested in a bone augmentation model in rabbits.  
 
2. Materials and methods 
2.1. Detection of the Release Profile 
2.1.1 Iodination of rhBMP-2 
rhBMP-2 was labeled with radioactive 125I by the Iodogen method. 50 µg Iodogen (Thermo 
Fisher Scientific, IL, USA) was dissolved in 500 pl ethyl acetate and added to a conical glass 
tube. The solvent was evaporated gently with a stream of N2. 297 µl of TU buffer (25 mM 
Tris, 6 M urea) pH 7.0 containing 100 µg rhBMP-2 were added to the coated glass tube and 
placed on ice. 3 µl of 125I stock solution (Iodine-125 radionuclide, specific activity ~17 Ci/mg, 
10 µM in NaOH pH 8-11, Nr. NEZ033A002MC, Perkin Elmer, MA, USA) were added and the 
mixture was incubated for 15 min. Free 125I was separated from the labeled protein by 
loading the reaction mixture on a pre-equilibrated PD-10 column (GE Healthcare, UK) and 
eluting it with TU pH 7.0 in 1 ml fractions. The radioactivity of the fractions was analyzed by a 
gamma counter (Cobra II Auto-Gamma, Packard) and the fractions containing the protein 
were pooled. The protein was concentrated and the buffer was exchanged to 1 mM HCl 
using centrifugal filter devices (Millipore, MA, USA) with a molecular weight (MW) cutoff of 10 
kDa. The iodinated protein was characterized by means of SDS PAGE and FPLC. 
2.1.2 SDS PAGE with Autoradiography 
Samples containing rhBMP-2 were mixed with 5x sample buffer (10% w/v SDS, 10 mM 
dithiothreitol (optional, for reduction), 20% v/v glycerol, 0.2 M Tris-HCl pH 6.8, 0.05% w/v 
bromophenol blue) in a ratio of 1:5. The mixture was incubated at 95 °C for 10 min and, 
together with MW markers, subjected to gel electrophoresis using a 4% stacking gel and a 
15% running gel. The gels were stained with Coomassie (0.01% Coomassie brilliant blue, 
50% methanol, 7% acetic acid), destained in a solution containing 25% methanol and 7% 
acetic acid and finally dried onto filter papers under vacuum at 80 °C. The dried gels were 
scanned with a standard desktop scanner. If radioactive 125I labels were used, a phosphor 
screen (Precisely Super Resolution, PerkinElmer) was exposed to the dried gel and a 
cyclone plus phosphor imaging system (PerkinElmer) was used to digitalize autoradiography 
intensities. The digital data was edited with OptiQuant 5.0 software (PerkinElmer). 
2.1.3 Fast Protein Liquid Chromatography with Autoradiography 
Analysis of rhBMP-2 was performed on a Superdex 75 size exclusion column (GE 
Healthcare, UK) on a fast protein liquid chromatography (FPLC) system from BioRad (CA, 
USA) connected to a gamma counter as well as a UV detector. Samples were loaded and 
eluted using TU buffer pH 7.0 containing 0.5 M NaCl and 0.1% Tween20 at a flow speed of 1 
ml/min. 
2.1.4 Functionalization of Apatite Granules with rhBMP-2 
The here investigated materials were DBBM (kindly provided by Geistlich Biomaterials) and 
HA/TCP (kindly provided by the Institut Straumann AG, Switzerland) granules, an overview 
over their properties is given in  
. The bone substitute materials were plasma cleaned in a radio-frequency oxygen plasma 
chamber (RF plasma chamber) at an oxygen pressure of 0.1 mbar to render the surface 
hydrophilic. In order to adsorb rhBMP-2 or 125I-rhBMP-2 to DBBM or HA/TCP from solution, 
21.4 mg of DBBM or HA/TCP were mixed with 50 µl 1 mM HCl containing 1.9 µg rhBMP-2. 
The mixture was vortexed, briefly spun down (10600xg, 10s) in a centrifuge and incubated 
overnight. Controls were prepared without the addition of rhBMP-2. Additional DBBM 
controls were immersed in FBS (Invitrogen, CA, USA) instead of 1 mM HCl. The next day the 
liquid remaining from the adsorption procedure was transferred to another tube and the 
concentration of 125I-rhBMP-2 adsorbed to the apatite granules and remaining in solution was 
determined by a gamma counter. 
2.1.5 Release Experiment 
The study design was equal to our previous study on interactions of rhBMP-2 with DBBM 
[21] (
 
Figure 1). Samples and controls were prepared as described in section 2.1.4. Concentration 
of 125I-rhBMP-2 adsorbed to the apatite granules was determined by measuring radioactivity 
of the whole sample and the supernatant with a Cobra II gamma counter. The liquid 
remaining from the adsorption procedure was discarded subsequently and the rhBMP-2 
loaded materials were transferred to new tubes containing differentiation medium (MEM-α 
(Invitrogen, CA, USA) supplemented with 10% FBS (Invitrogen,), ascorbic acid (50 mg/l, 
SigmaAldrich, MO, USA) and antibiotics (100 U/ml penicillin G and 100 mg/ml streptomycin, 
Invitrogen)). The final volume was calculated to be 1 ml, the volume of apatite granules not 
taken into account. The amount of 125I-rhBMP-2 transferred to the new tubes was determined 
by measuring the radioactivity of the whole samples. After incubation of the controls for 1h, 
allowing interaction of the bone substitute materials with the differentiation medium, 1.9 µg 
125I-rhBMP-2 were added. All samples were incubated at 37 °C. The amount of 125I-rhBMP-2 
in the whole samples as well as in 10 µl of the supernatant was evaluated at various time 
points by measuring the gamma radiation. The amount of 125I-rhBMP-2 adsorbed to apatite 
granules or in solution was evaluated by comparing values from the samples with the 
positive controls. The removed supernatant was not replaced but taken into account for 
calculations of the cumulative release/adsorption. Each sample and control was prepared six 
times (n=6) and the experiment was repeated. After 15 days of incubation, the supernatant of 
the samples was evaluated on SDS-PAGE gels and using FPLC. 
2.2. Cell Experiments 
2.2.1 Cell Culture Maintenance 
MC3T3-E1 cells (Subclone 24, ATCC, VA, USA) were expanded in proliferation medium 
(MEM-α (w/o ascorbic acid) (Invitrogen) supplemented with 10% FBS (Invitrogen) and were 
used for experiments between passage three and ten. Cells were never allowed to become 
confluent and split in a ratio of 1:5. All experiments were carried out in differentiation 
medium. For experiments in 24- or 48-well plates, cells were seeded at a density of 10'000 
cells/cm2. 
2.2.2 Assay for Alkaline Phosphatase Activity 
Cells were stimulated for 7 days at 37 °C and 5% CO2. They were subsequently lysed using 
0.56 M 2-amino-2-methyl-1-propanol (SigmaAldrich) pH 10 containing 0.2% Triton X-100 
(SigmaAldrich). Alkaline phosphatase (ALP) activity in the lysis buffer was determined via the 
kinetics of a colour reaction based on the reduction of p-nitrophenyl phosphate 
(SigmaAldrich) to p-nitrophenol. The DNA concentration of the lysate was determined using 
a PicoGreen assay according to the instructions of the manufacturer (Invitrogen). Optical 
density of the ALP activity reaction product p-nitrophenol (410 nm) and fluorescence of DNA 
bound PicoGreen (ex/em ~480 nm/~520 nm) was detected with a Synergy HT plate reader 
(Biotek, VT, USA). The determined ALP activity was adjusted to the total cell number by 
standardizing it to the DNA concentration in the sample. 
2.2.3 Cell Stimulation with completely released rhBMP-2 
rhBMP-2 was released into differentiation medium from DBBM and HA/TCP granules for 15 
days as described in section 2.1.4 and section 2.1.5. The conditioned differentiation medium 
supernatant from samples and controls was diluted 1:1 in fresh differentiation medium before 
stimulating MC3T3-E1 cells. Cells were incubated at 37 °C and 5% CO2, and osteoblastic 
differentiation was evaluated after 7 days of incubation by an ALP activity assay as described 
earlier. 
2.2.4 Continuous Stimulation of Cells with Transwell Membranes 
DBBM and HA/TCP granules loaded with 1 µg rhBMP-2 as well as controls were prepared as 
described in section 2.1.4. MC3T3-E1 cells were seeded in 1 ml cell culture medium on the 
bottom of 24-well plates in differentiation medium. rhBMP-2-loaded granules and control 
granules were placed in the wells containing the cells, separated from the cells via a 
transwell membrane insert (Polyester (PET) Membrane Transwell-Clear Inserts, 24-well 
plate, 3.0 µm pore size, Corning, NY, USA) permeable for rhBMP-2. rhBMP-2 for positive 
controls was added to the upper part of the transwell compartment and cells were incubated 
at 37 °C, 5% CO2. Osteoblastic differentiation was evaluated by an ALP activity assay as 
described in section 2.2.2 after 7 days of incubation. 
2.3. Animal Experiments 
2.3.1 Cleaning and Sterilization of Titanium Cylinders 
Titanium cylinders were manufactured in the machine shop at the Materials Department of 
ETH Zurich (Switzerland) as described earlier [22]. Cylinders were immersed in 
approximately 50 ml acetone, sonicated for 15 min and rinsed with plenty of water (3x), 
immersed in approximately 50 ml 2-propanol, sonicated for 15 min and rinsed with plenty of 
water (3x), immersed in approximately 50 ml of ultrapure water (MilliQ, Millipore, MA, USA) 
dried at 37 °C overnight and vapor sterilized (134 °C) in the central sterilization facilities of 
the University Hospital Zurich (Switzerland). 
2.3.2 Functionalization of Apatite Granules with rhBMP-2 
DBBM and HA/TCP were plasma cleaned in a radio-frequency oxygen plasma chamber (RF 
plasma chamber) at an oxygen pressure of 0.1 mbar. Weight per volume of granules was 
determined for both DBBM and HA/TCP by filling a 0.2 ml RT/PCR tube and determining its 
weight increase. Based on these results, 750 mg of DBBM or 825 mg HA/TCP were mixed 
with 3000 µl 1 mM HCl containing 75 µg rhBMP-2. By choosing these ratios, the amount of 
bone substitute needed to fill a cylinder was loaded with 10 µg rhBMP-2 for both materials. 
The mixture was vortexed, briefly spun down (10600xg, 10s) in a centrifuge and incubated 
overnight. Controls were prepared without the addition of rhBMP-2. The next day the 
samples were frozen by immersion in liquid nitrogen and lyophilized. 
2.3.3 Surgery 
6 rabbits were sedated by Ketamin and further anaesthetized by an Isofluran-N2O inhalation 
method. A linear incision was made from the nasal bone to the midsagital crest. After the 
deflection of the soft tissues, a sub periosteal dissection of the operation site was performed 
(occipital, frontal, and parietal bones). To place the specially designed cylinder made of c.p. 
titanium with a machined surface four evenly distributed 6 mm diameter circular slits with a 
1mm sink depth were created and perforations of the external cortical plate inside the slits 
were prepared. The cylinders measured 7 mm in height and 7 mm in outer diameter and 
exhibited a screw design toward the bone site and a small shoulder for a titanium lid toward 
the covering skin flap. The surgical area was rinsed with saline to remove bone debris and 
four cylinders were screwed in the prepared slits, providing primary stability. Next, the 
cylinders were filled with DBBM, DBBM/rhBMP-2, HAT/TCP, or HA/TCP/rhBMP-2. The 
cylinders fillings were assigned in a random systematic manner. The cylinders were left open 
toward the bone but were closed with a titanium lid designed to press fit into the opening. 
After placement of the lids, the soft tissues were closed with sutures. Analgesia was provided 
by injection of Novalgin® (50 mg/kg; Aventis Pharma AG, Zürich, Switzerland). At 8 weeks 
the rabbits were sacrificed after sedation with barbiturates by an overdose of Ketamin® 
(Pfizer AG, Zürich, Switzerland) and the calvarial bone was excised. 
2.3.4 Histological analyses  
Samples were prepared as described earlier [23]. In brief, the samples were first prepared 
with a sequential water substitution process and further infiltrated by methyl methacrylate. 
Samples were allowed to polymerize at 37°C in an air tight water bath. The specimens were 
sectioned in the frontal plane through the middle of the cylinders. Sections of 200 µm 
thickness were obtained, ground, and polished to a uniform thickness of 60–80 µm. The 
specimens were surface stained with toluidine blue. 
2.3.5 Histomorphometry 
Measurements were carried out on a picture mosaic taken from the entire area of interest via 
a light microscope at a magnification of 160x, using a superimposed test grid of points and 
cycloid lines. The numbers of test points overlying the profiles of the different components 
(i.e. mineralized bone tissue, non-mineralized tissue and graft particles) were counted. Test 
points are defined and symbolized according to the standard nomenclature of the 
International Society for Stereology [24]. The graft to bone contact was calculated by the 
number of intersections between graft particles and the outlines of either mineralized bone or 
non-mineralized tissue. 
In addition, a quantitative evaluation of the area of bone augmentation within the cylinders 
was carried out to extract a clinically relevant parameter. First digital images were obtained 
and processed with an image analysis program (Adobe Photoshop CS3). The pixel counts 
were directly carried out on the digital images and comprised the area of newly formed bone, 
including bone marrow and osseointegrated bone substitute particles.  
 
2.4. Statistical Analysis  
The primary unit of analysis was the animal. Mean values and standard deviations were 
calculated for the area of osseous regeneration, absolute bone points, absolute bone 
substitute points, and for the percentage of bone-to-bone substitute contact in the middle 
section within the cylinder. The significance of differences was evaluated by the Friedman 
test followed by Wilcoxon signed rank test. The limit for significance was set to <0.05. 
Statistical analysis was performed by using a statistical software package (IBM SPSS 
Statistics Version 21 for Windows). 
3. Results 
3.1. Characterization of the Iodinated rhBMP-2 
rhBMP-2 was labeled with radioactive iodine (125I-rhBMP-2) in order to simplify the detection 
of the released growth factor. We evaluated the functionalized protein by means of SDS 
PAGE and FPLC. The FPLC chromatograms of rhBMP-2 and 125I-rhBMP-2 are alike (Figure 
2 B) and we detected similar MW bands for 125I-rhBMP-2 and rhBMP-2 on reduced SDS 
PAGE gels. However, we observed a second band for 125I-rhBMP-2 on the non-reduced 
SDS-PAGE gels (Figure 2 A; lane 2 and 5). 
3.2. Release Profiles from Substitute Materials 
Overnight incubation of rhBMP-2 to the apatite materials in 1 mM HCl led to the adsorption of  
67% ± 5% and 51% ± 7% of the applied 125I-rhBMP-2 to HA/TCP and DBBM respectively. To 
study the release of the adsorbed rhBMP-2, the apatite granules were transferred to new 
tubes containing differentiation medium. The release profile of previously adsorbed 125I-
rhBMP-2 from HA/TCP and DBBM samples (Fig. Fehler! Verweisquelle konnte nicht 
gefunden werden.3A) as well as the interaction of 125I-rhBMP-2 with HA/TCP and DBBM 
controls in differentiation medium (Fig.Fehler! Verweisquelle konnte nicht gefunden 
werden. 3B) was evaluated by determining concentrations of the growth factor in the 
supernatant and in the whole sample using a gamma counter. After an initial burst release, 
DBBM showed a slow release during 15 days and was capable of retaining half of the 
adsorbed growth factor. 125I-rhBMP-2 showed a strong affinity to DBBM in the controls, even 
if the DBBM was preincubated in FBS prior to its immersion in differentiation medium. 
HA/TCP samples showed a burst release and the complete amount of adsorbed 125I-rhBMP-
2 was released after 24h. We did not observe any interactions between 125I-rhBMP-2 in the 
controls. 
3.3. Biological Activity of Released rhBMP-2 
Effect of rhBMP-2 released from DBBM and HA/TCP on MC3T3-E1 was evaluated in vitro by 
stimulating them either with the supernatant of a 15 days release (endpoint, section 2.1.3 ) or 
by separating the cells from the rhBMP-2 loaded granules via a transwell membrane 
permeable for rhBMP-2 (continuous, section 2.3.40). Cell viability was affected by the 
presence of DBBM in the continuous approach as indicated by a reduced cell number 
(Figure 4 A). The presence of rhBMP-2 slightly increased cell viability in all samples. 
We did not detect any significant differences between ALP activities of cells stimulated by the 
endpoint or the continuous method (Figure 4 B). While functionalization of HA/TCP with 
rhBMP-2 leads to an ALP response comparable to the positive controls containing the same 
amount of rhBMP-2 but no apatite granules, the combination of DBBM and rhBMP-2 leads to 
a reduced ALP activity compared to the positive control. 
3.4. In vivo bone augmentation model 
After operation, all animals showed uneventful healing of the area of surgery. In none of the 
samples signs for immunoreactions or inflammation were seen. The external and internal 
cortical plates of the cranium were clearly visible on the histological specimens (Figure 5). 
The toluidine blue staining allowed a clear distinction between the graft material and the 
regenerated bone (Figure 5). Bone formation close to the skull was more frequent, indicating 
an upwards movement of the bone front, even in the rhBMP-2 loaded samples. 
The area of bone formation comprises the area where bone formation had occurred; 
specifically the area where ingrowing interconnected bone tissue has covered bone 
substitute materials. Compared to all other groups the values for the DBBM/rhBMP-2 group 
was significantly higher (Figure 6 A), indicating that in the presence of rhBMP-2 in 
combination with DBBM bone augmentation was enhanced. The number of bone points 
which equals new bone formation, however, did not vary significantly between the groups 
(Figure 6 B). Therefore rhBMP-2 accelerated mainly the advancement of the bone front from 
bottom to the top of the cylinder in the DBBM/rhBMP-2 group. 
Although both HA/TCP and DBBM are apatites, their geometry, microporosity, and the 
degradation in particular of the TCP vary (Table 1), resulting in different apparent densities of 
the granules that result in a higher number of bone substitute material points in the 
DBBM/rhBMP-2 group compared to both HA/TCP containing groups (Figure 6 C). 
Of clinical relevance is the extent of the area of bone formation (Figure 6 A) but also the 
integration of the bone substitute into newly forming bone, since it is an indication for the 
stability of the resulting bone/bone substitute construct and indicative for its integration into 
normal bone turn over. The level of bone to bone substitute material interface is 36.0 ± 2.9% 
for DBBM and 33.7 ± 3.8% for DBBM/rhBMP-2 respectively. For HA/TCP, however, this 
number was much lower with 24.0 ± 3.5% but was significantly increased by BMP to 33.2 ± 
1.4% in the HA/TCP/rhBMP-2 group (Figure 6 D). 
4. Discussion 
We here evaluated two clinically applied apatite based bone substitute materials in terms of 
their potential for a combination with the osteoinductive growth factor rhBMP-2. In a previous 
study we used an ELISA specific for rhBMP-2 to detect the growth factor [21]. However, this 
method has several drawbacks. The growth factor is recognized by an antibody and its 
detection is therefore dependent on the accessibility of the recognized epitope. Although the 
epitope recognition could be indicative for the proper folding and bioactivity, this assay is 
very susceptible to buffer changes and the presence of other molecules. We therefore 
labeled rhBMP-2 with radioactive iodine (125I) via the Iodogen method. Evaluating the labeled 
growth factor by comparing its FPLC size exclusion chromatogram to the native rhBMP-2 we 
did not find any differences (Figure 2 B). We further compared native rhBMP-2 and 125I-
rhBMP-2 on an SDS PAGE gel under reducing and non-reducing conditions. While we did 
not find any differences between the molecular weight detected in case of the reduced 
samples, we found a weak additional band in case of 125I-rhBMP-2 under non-reducing 
conditions (Figure 2 A) indicating that some of the dimers might have undergone a slight 
modification in their secondary structure which is reflected in a reduced bioactivity of the 
growth factor (data not shown). The data suggests that the primary structure of the growth 
factor was not affected by the iodination and the secondary structure was only affected in a 
small portion of the applied rhBMP-2. 
In a clinical setting the granules can be loaded in the operation theatre and then transferred 
into the patient. Therefore we studied the release from loaded granules to mimic better 
clinical conditions. In our previous study [21] we added the cell culture medium to the same 
tubes where the adsorption of rhBMP-2 from 1 mM HCl was performed. Determining the 
amount of rhBMP-2, we found that more rhBMP-2 was transferred by HA/TCP than had been 
transferred by DBBM. The release profile of rhBMP-2 from DBBM however confirmed our 
previous results showing a high affinity of rhBMP-2 to DBBM. DBBM was capable of 
retaining half of the adsorbed growth factor in differentiation medium during 15 days (Figure 
3 A). In contrast, all rhBMP-2 adsorbed to HA/TCP was released during the initial 24h. These 
results are confirmed by the control samples where the apatite materials were preincubated 
in differentiation medium for 1h and the rhBMP-2 was added subsequently. We further 
preincubated DBBM in FBS overnight and still saw adsorption of rhBMP-2. Therefore, 
rhBMP-2 adsorbs to DBBM even in the presence of serum proteins [21]. In contrast to this 
there was no interaction between rhBMP-2 and HA/TCP in the control samples (Figure 3 B), 
indicating that the growth factor has a low affinity to HA/TCP under physiological conditions 
and that the investigated HA/TCP granules are not a slow release system for rhBMP-2. This 
lack of affinity of rhBMP-2 for HA/TCP could be the reason for the failure to get AMPLIFY™ 
cleared for use in humans, since the high load of rhBMP-2 might have been release too fast, 
was not retained at the application site and induced cancer formation at various locations in 
the body [5]. 
DBBM is mainly composed of hydroxyapatite. The difference in absorption and release of 
rhBMP-2 might not derive from the difference between hydroxyapatite and β-tricalcium 
phosphate, since it was shown by others that after 24 h 49.6% of rhBMP-2 can still be 
associated with β-tricalcium phosphate and 34.0 % with hydroxyapatite [25]. In that study the 
specific surface of both materials was very similar ranging from 1 to 4 m2/g. In our case, 
however, DBBM has a surface area of 67 m2/g and the HA/TCP of 0.009 m2/g. This suggests 
that the affinity and release kinetic of rhBMP-2 to calcium phosphates is determined mainly 
by the specific surface area, which is extremely high with DBBM (Table 1). This conclusion is 
in line with results obtained for other proteins [20]. 
Stimulation of MC3T3 cells with rhBMP-2 released from both HA/TCP and DBBM revealed 
that most of the released growth factor was bioactive. Since there was more rhBMP-2 
transferred by HA/TCP than by DBBM and half of the transferred rhBMP-2 was retained by 
DBBM, there was much more ALP activity induced in samples with HA/TCP than those with 
DBBM (Table 1). We did not observe a marked difference in ALP activity between cells 
stimulated with the supernatant from a release (endpoint) or continuously stimulated by 
rhBMP-2 released from the bone substitute materials separated from the cells via a transwell 
membrane permeable for rhBMP-2. This suggests that after the burst released rhBMP-2, the 
rhBMP-2 that was slowly released from DBBM between day 2 and day 7 was either not 
bioactive or its amount too low, or the in vitro release kinetic ill-suited to be detected using 
this assay. This is in agreement with our previous results that did not show any slow release 
using an ELISA for the detection of rhBMP-2 which would not detect growth factors with a 
compromised structure [21]. 
Most in vitro tissue culture experiments represent a closed compartment where factors 
cannot diffuse out. In the clinical situation a closed compartment can be generated by the 
application of a membrane, a technique called guided bone regeneration, which is applied 
frequently in dentistry to augment sufficient bone for the placement of dental implants. To 
mimic this situation and to test both materials for bone augmentation, which is very 
demanding in the clinical setting, we applied our cylinder model, where titanium cylinders are 
placed on top of the calvarial bone and the content is restricted by the calvarial bone on one 
side and by titanium on all other sides [23] (Fig 1C). Bone augmentation, determined by the 
area of osseous regeneration, was significantly higher in the DBBM/rhBMP-2 group 
compared to all other groups. Therefore the efficiency of DBBM for bone augmentation could 
be further enhanced by the combination with rhBMP-2. Since the majority of the rhBMP-2 is 
bound to the DBBM granules it also suggests that even the rhBMP-2 strongly bound to 
DBBM retains sufficient bioactivity to push the bone augmentation front further. That tightly 
bound physio-absorbed rhBMP-2 can still be bioactive was shown for other materials before 
[26].  
The fast released rhBMP-2 in the HA/TCP/rhBMP-2 group estimated to be double the 
amount released from DBBM, however, failed to increase bone augmentation significantly. In 
vitro, all samples exposed continuously to DBBM showed a decrease in proliferation and 
ALP activity, which might derive not only from the high affinity of DBBM for rhBMP-2 but also 
for other proteinaceous factors, depriving the culture medium of factors needed by the cells 
in this artificial environment. In vivo, however, overall protein content is much higher. This 
effect, which most likely is due to the 1000 times higher specific surface area of DBBM 
compared to HA/TCP (Table 1) might not play any negative role at all. Therefore in vitro cell 
culture based tests of biomaterials have to be complemented by in vivo models. 
Recently it was shown that especially designed fast degrading TCP in contrast to slow 
degrading hydroxyapatite based materials are osteoinductive due to a release kinetic of 
calcium ions which can trigger signaling pathways via the protein kinase C pathway, leading 
to an increase in the expression of BMPs [8, 27]. For the ceramics we used in this study, 
neither the in vitro nor the in vivo results indicate any osteoinductive potential. Therefore the 
marked difference in the specific surface area appears to be the main reason for the superior 
performance of the DBBM in vivo. This is further supported by findings that an increase in 
specific surface area enhances not only the adsorption of proteins from plasma including 
fibronectin and vitronectin, but at the same time also stimulates osteoblast adhesion, growth 
and osteogenic differentiation [20].   
In a clinical trial to study bone augmentation for the placement of dental implants with DBBM 
with and without rhBMP-2 the amount of newly formed bone was not increased significantly 
but bone maturation and bone to DBBM contact was [28, 29]. Here the space was 
constrained by a guided bone regeneration membrane serving as a barrier to enhance bone 
regeneration. Although the time between operation and evaluation in the clinical trial was 6 
months the combination of DBBM with rhBMP-2 improved its performance significantly and 
supports our findings that rhBMP-2 bound to DBBM is bioactive and still capable to enhance 
bone augmentation. Therefore this combination appears very safe, since it induces bone 
formation just at the site where the material was placed.  
Bone to bone substitute contact was high for DBBM and could not be increased further when 
rhBMP-2 was applied. For HA/TCP, however, the initial level of bone to bone substitute 
contact was low and increased by the addition of rhBMP-2. Our in vitro experiments show 
that rhBMP-2 is not adsorbed by HA/TCP granules. This increase in bone to HA/TCP contact 
therefore indicates that the burst released rhBMP-2 still had some significantly positive 
effects in combination with HA/TCP, in particular since the diffusion was restricted by the 
titanium cylinder mimicking a guided bone regeneration scenario. The positive effect could 
further be caused by the lyophilization procedure during the preparation of the samples. 
Small amounts of rhBMP-2 clusters could remain attached to the surface and induce a better 
bone/bone substitute interface. 
5. Conclusions 
The comparison of two ceramics as potential delivery systems for rhBMP-2 revealed that 
DBBM, which has a 1000 fold higher specific surface area, adsorbs rhBMP-2 efficiently and 
keeps 50% of it attached for more than two weeks. From the HA/TCP material all rhBMP-2 is 
released in a burst during the first 24h. The released rhBMP-2 from both materials remains 
bioactive. In vivo DBBM performs better in terms of bone augmentation and bone to implant 
contact. By the addition of rhBMP-2 both parameters are further improved and bone 
augmentation is significantly higher. In combination with rhBMP-2 both parameters are 
increased for HA/TCP but only bone to bone substitute contact increased significantly. 
Therefore the addition of rhBMP-2 can cope to some extend for a low specific surface area. 
DBBM appears to be a very safe delivery system for rhBMP-2 since 50% of the rhBMP-2 
remains absorbed but active, keeping the rhBMP-2 activity restricted to the site where the 
osteoinductive bone substitute was placed. 
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8. Figure legends 
 
Figure 1: In vitro and in vivo settings. A) Schematic drawing of the setup for in vitro release. 
B) Schematic drawing of the setup for cell culture experiments. Endpoint stimulation: rhBMP-
2 was released from granules into differentiation medium for 15 days. Granules were 
separated from the supernatant that was used to stimulate MC3T3-E1 cells. Continuous 
stimulation: rhBMP-2 loaded granules were separated from cells via a transwell membrane 
permeable for rhBMP-2. C) 4 titanium cylinders are placed on top of the calvarial bone (left 
panel). After filling with materials, the cylinders are closed by a press fitted titanium lid (right 
panel). 
 
 
 
 
Figure 2: Evaluation of the iodination of rhBMP-2. A) SDS PAGE gel stained with Coomassie 
and investigated for autoradiography. 1) marker; 2) 1 µg 125I-rhBMP-2; 3) & 4) 1 µg rhBMP-2; 
5) & 6) 80 ng 125I-rhBMP-2; 7) & 8) 1 µg rhBMP-2; 9) 1 µg 125I-rhBMP-2. Bands of lanes 5) 
and 6) were detected by autoradiography. While there is no difference in MW between 
rhBMP-2 and 125I-rhBMP-2 if the protein has been reduced by DTT, a second band can be 
observed for 125I-rhBMP-2 under non-reducing conditions (lane 2 and 5). B) Typical FPLC 
chromatogram of rhBMP-2 and 125I-rhBMP-2 detected via UV detector and scintillation 
counter respectively. We did not observe differences between the chromatograms of the 
labeled and the unlabeled protein. 
 
 
 
Figure 3: 125I-rhBMP-2 release and absorption from and to HA/TCP and DBBM. A) In vitro 
release of 125I-rhBMP-2 from HA/TCP and DBBM into differentiation medium at 37 °C. While 
almost all 125I rhBMP-2 is immediately released from HA/TCP, DBBM is capable of retaining 
a large fraction of 125I-rhBMP-2 during 15 days of incubation. B) In vitro absorption of 125I-
rhBMP-2 to HA/TCP and at 37 °C. While there is no interaction between 125I-rhBMP-2 and 
HA/TCP granules in cell culture medium, the growth factor adsorbs to DBBM even in the 
presence of FBS in the cell culture medium. Preincubation of DBBM with FBS does not 
prevent 125I-rhBMP-2 from adsorbing, indicating that the affinity of 125I-rhBMP-2 to DBBM is 
higher than the affinity of serum proteins. 
 
 
 
Figure 4: Biological activity of rhBMP-2 released from DBBM and HA/TCP. A) Cell viability by 
DNA content. rhBMP-2 increases cell viability. The presence of DBBM in vitro (continuous 
method) affects cell viability. B) ALP activity induced by the released rhBMP-2. While almost 
all rhBMP-2 is released from HA/TCP that induces an ALP activity only slightly lower than in 
the positive controls, large amounts of rhBMP-2 are retained by the DBBM resulting in a 
much lower ALP activity. 
 
 
Figure 5: Bone augmentation by bone substitutes. In the rabbit cylinder model, bone 
augmentation was compared between cylinders filled with DBBM (A), HA/TCP (B), 
DBBM/rhBMP-2 (C) and HA/TCP/rhBMP-2. Bone is stained by toluidine blue as bright blue, 
bone substitutes are stained purple (DBBM) or black (HA/TCP). The titanium cylinders to the 
left and right side of each sample appears black. In the lower part of each sample the original 
calvarial bone is seen. The scale provided in the lower part shows 0.1 mm.   
 
 
 
 
 
Figure 6: Histomorphometric results from the bone augmentation experiment. For all four 
materials, DBBM, DBBM/rhBMP-2, HA/TCP and HA/TCP/rhBMP-2, the area of osseous 
regeneration (A), absolute bone points (B), absolute bone substitute points (C), and bone to 
implant contact (D) is displayed. Values are given as box-plots ranging from the 25th (lower 
quartile) to the 75th (upper quartile) percentile including the mean and whiskers showing the 
minimum and maximum values. The P values of all statistically significant differences are 
provided.  
 
